ATUM to offer Protein Synthesis Platform to COVID-19 test tool developers
Category: #health  By Mateen Dalal  Date: 2020-03-27
  • share
  • Twitter
  • Facebook
  • LinkedIn

ATUM to offer Protein Synthesis Platform to COVID-19 test tool developers

As the coronavirus pandemic reaches community level, prominent companies have come forward to aid medical researchers in accelerating their drug development process. ATUM, an American biotechnology firm, recently made a similar move when it revealed that it would offer access to its Leap-In Transposase® protein production solution for free to all academic and commercial laboratories that are creating vaccines, new protein-based therapies and diagnostic tools for combating the COVID-19.

With a broad range of antibodies, viral proteins, and interleukins along with other related protein molecules presently being tested under COVID-19-related trials, ATUM’s biological Leap-In platform would facilitate rapid development of commercial-grade protein up to kilogram levels.

Apparently, the effective cell-based protein production could play a vital role in ramping up the manufacturing of protein-based therapeutics, diagnostic tests, and vaccines.

ATUM’s Leap-In Transposase solution also allows a stable and rapid gene integration for the expression of complex and simple proteins from mammalian hosts. Additionally, antibody production titers surpassing 5g/L could be attained under a few weeks. In fact, the platform is being used by leading pharmaceutical and biotechnology firms across the world.

Meanwhile, other biotech firms are also boosting their developmental efforts in order to formulate a treatment for COVID-19. For instance, San Francisco-based biotech firm, Genentech is forming strategic alliance with the FDA to run a phase-three trial that examines if its existing medicines are effective enough to combat the virus.

Commenting on the move, Dr. Levi Garraway, Chief Medical Officer, Genentech, said that the company is commencing a clinical study with one of its drugs called Actemra to test if it is effective against COVID-19 pneumonia.

As for Claes Gustafsson, Co-founder, ATUM, the firm’s labs are busier than normal and have even reached out to other local labs for finding a cure for this disease.

Source Credit: https://apnews.com/Business%20Wire/e8918decc19f49289d7f70865626c041

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

AstraZeneca to present results of Farxiga’s DAPA-CKD trial at ESC 2020
AstraZeneca to present results of Farxiga’s DAPA-CKD trial at ESC 2020
By Mateen Dalal

According to reliable sources, British-Swedish multinational pharmaceutical company AstraZeneca plc will present the much awaited results of the Phase III DAPA-CKD trial of Farxiga in CKD (chronic kidney disease) at ESC Congress 2020. Sources with r...

FDA grants Emergency Use Authorization to Abbott’s COVID-19 antigen
FDA grants Emergency Use Authorization to Abbott’s COVID-19 antigen
By Mateen Dalal

Abbott Laboratories, a U.S.-based medical devices and healthcare firm, has reportedly received the Emergency Use Authorization (EUA) from the U.S. FDA (Food and Drug Administration) for the detecting COVID-19 virus with its portable antigen test Bina...

Hyundai Wia Corp. signs gun parts export contract with BAE Systems
Hyundai Wia Corp. signs gun parts export contract with BAE Systems
By Mateen Dalal

Hyundai Wia Corp., a South Korea-based defense firm, has reportedly signed gun parts export contract with BAE Systems plc of worth USD 100 million via a pre-value accumulation system. As per the agreement, Hyundai Wia will supply over 106 types of gu...